Exicure, Inc. (NASDAQ:XCUR) Sees Significant Growth in Short Interest

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 31,100 shares, a growth of 72.8% from the October 15th total of 18,000 shares. Approximately 4.7% of the company’s shares are sold short. Based on an average daily trading volume, of 1,030,000 shares, the short-interest ratio is currently 0.0 days.

Exicure Stock Down 15.2 %

Shares of NASDAQ XCUR opened at $2.73 on Thursday. The company has a market capitalization of $4.72 million, a PE ratio of -0.62 and a beta of 1.28. Exicure has a twelve month low of $1.44 and a twelve month high of $6.00. The firm has a fifty day simple moving average of $2.69 and a 200 day simple moving average of $1.26.

Exicure (NASDAQ:XCUR) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter.

Insider Buying and Selling at Exicure

In related news, major shareholder Co. Ltd. Dgp acquired 237,223 shares of the stock in a transaction dated Thursday, September 12th. The stock was bought at an average cost of $3.00 per share, for a total transaction of $711,669.00. Following the completion of the transaction, the insider now directly owns 849,223 shares of the company’s stock, valued at $2,547,669. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 3.90% of the company’s stock.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.